Strategies for optimizing treatment with efalizumab in moderate to severe psoriasis

Journal of Cutaneous Medicine and Surgery
Kim A PappCatherine Zip

Abstract

With the advent of biological therapies for the treatment of plaque psoriasis, guidance on the usage of these new agents has become necessary. One such agent, efalizumab, a humanized recombinant monoclonal IgG(1) antibody developed to target T-cell-mediated inflammation, provides rapid and sustained efficacy for many psoriasis patients. This article explores the pretreatment, initiation, and treatment phases with efalizumab therapy. In the pretreatment phase, physicians need to assess patients' disease state and educate them about the course of efalizumab treatment. Prior to initiation, physicians need to establish stable disease, ensure an adequate transition or washout of any prior psoriasis therapeutics, and obtain baseline platelet counts. After initiating treatment, both physician and patient must participate in disease monitoring. Patients responding favourably may receive continuous treatment. Those who do not respond to the drug or who experience adverse events should be managed appropriately in order to continue therapy or be transitioned onto another agent. A growing body of clinical evidence, as well as experience from clinical investigators, has provided much insight into the management strategies for patients under...Continue Reading

References

Mar 1, 1993·Journal of the American Academy of Dermatology·G D Weinstein, G M White
Apr 20, 2000·Journal of Clinical Pharmacy and Therapeutics·D M AshcroftC E Griffiths
May 22, 2002·Archives of Dermatology·Prashant SingriKenneth B Gordon
Oct 17, 2002·Drug Safety : an International Journal of Medical Toxicology and Drug Experience·Stacy L McClureKenneth B Gordon
Jan 25, 2003·The Journal of Investigative Dermatology·Carle F PaulLouis Dubertret
Apr 11, 2003·Lancet·Mark Lebwohl
Jul 4, 2003·The Journal of Investigative Dermatology·Heinrich DickelThomas L Diepgen
Apr 13, 2004·Clinical Oncology : a Journal of the Royal College of Radiologists·M Clemons
Jan 19, 2005·Archives of Dermatology·Kenneth B GordonGerald Krueger
Feb 21, 2006·Journal of the American Academy of Dermatology·Wayne CareyDarryl Toth
Feb 21, 2006·Journal of the American Academy of Dermatology·Alan MenterKim A Papp
Apr 25, 2006·Journal of Cutaneous Medicine and Surgery·Neil H ShearVincent Ho

❮ Previous
Next ❯

Citations

Jun 30, 2009·Actas dermo-sifiliográficas·L PuigUNKNOWN Grupo Español de Psoriasis de la Academia Española de Dermatología y Venereología
Aug 30, 2008·Clinics in Dermatology·Kim A Papp
Apr 16, 2008·Journal of the European Academy of Dermatology and Venereology : JEADV·E Adíşen, M A Gürer
Jan 10, 2020·The Cochrane Database of Systematic Reviews·Emilie SbidianLaurence Le Cleach

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.